CTLA4 and metastatic melanoma: In germ-free mice that developed metastatic melanoma, CTLA-4 therapy had insufficient antitumor effects due to limited effector CD4+ T cells and tumor-infiltrating lymphocytes, but oral administration of Bacteroides and Burkholderia species improved efficacy of the CTLA-4 therapy with better antitumor effects (121).